Results 181 to 190 of about 268,545 (217)
Some of the next articles are maybe not open access.
Treatment of seizures with medroxyprogesterone acetate
Neurology, 1984Medroxyprogesterone acetate (MPA), a synthetic progesterone, was added to the antiepileptic drug regimen of 14 women who had uncontrolled seizures. Of the 11 women who developed amenorrhea, 7 reported fewer seizures during MPA therapy. Overall reductions in seizure frequency averaged 30% (n = 11), declining from a baseline 8.3 +/- 5.8 seizures per ...
R H, Mattson +3 more
openaire +2 more sources
Effect of Medroxyprogesterone Acetate on Peritoneal Adhesion
Asia-Oceania Journal of Obstetrics and Gynaecology, 1988AbstractSixteen albino female non‐pregnant rabbits of the blanc du Bouscat strain are the material of this study. Ten animals received a single intramuscular injection of 20 mg medroxyprogesterone acetate (MPA). The other six received placebo (normal saline).
S A, Nayel +3 more
openaire +2 more sources
MANAGEMENT OF ENDOMETRIOSIS WITH ORAL MEDROXYPROGESTERONE ACETATE
Obstetrical & Gynecological Survey, 1976Efficacy of oral medroxyprogesterone acetate (MPA) was assessed in 35 women with an established diagnosis of endometriosis (33 pelvic and 2 abdominal). MPA was given in a dosage of 30 mg daily for 90 days. Results indicated improvement or remission in all cases, even though breakthrough bleeding occurred in 8.
K S, Moghissi, C R, Boyce
openaire +2 more sources
Endocrine Manipulation of Meningiomas with Medroxyprogesterone Acetate
Surgical Neurology, 1989Medroxyprogesterone acetate (MPA) acted as a competitive binder to progesterone receptors (PR) of meningioma cytosols after in-vivo administration (PRmean =15.6 fmol/mg protein 338.3 fmol/g tumor, n = 15), in comparison to 54.9 fmol/mg protein (2813 fmol/g tumor) in our untreated meningioma series (n = 58).
Ernst R. Waelti, Thomas-Marc Markwalder
openaire +1 more source
The Effect of Medroxyprogesterone Acetate on Blood Pressure
International Journal of Gynecology & Obstetrics, 1979ABSTRACTTwenty‐four women (21 normotensive and 3 hypertensive) aged 16–35 years received 150‐mg injections of medroxyprogesterone acetate (MPA) for contraception. Their blood pressure (BP) was measured under basal conditions by the same nurse before treatment and at 1‐, 2‐ and 3‐month intervals. Their mean BP fell from 124.1/79.4 to 119.8/74.6 mm Hg at
H R, Black, P, Leppert, A, DeCherney
openaire +2 more sources
Treatment of sex offenders with medroxyprogesterone acetate
American Journal of Psychiatry, 1981Forty-eight male patients with long-standing histories of deviant sexual behavior received medroxyprogesterone acetate and milieu therapy for up to 12 months. Forty subjects responded positively, all within 3 weeks, with diminished frequency of sexual fantasies and arousal, decreased desire for deviant sexual behavior, increased control over sexual ...
openaire +2 more sources
Pharmacist-administered depot medroxyprogesterone acetate
Contraception, 2006Continuation rates for women using depot medroxyprogesterone acetate (DMPA) for contraception in the United States are very low. Compliance/continuation rates at 3 months range from 57% to 71% with usual care and follow-up. At 6 months the range decreases to between 35% and 63%. The continuation rate at 1 year ranges from 23% to 45%.
openaire +2 more sources